{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:08:32Z","timestamp":1787062112030,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR002377"],"award-info":[{"award-number":["UL1 TR002377"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.mayocp.2018.08.002","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T19:30:00Z","timestamp":1548963000000},"page":"500-514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Prediction of the Renal Elimination of Drugs With Cystatin C vs Creatinine: A Systematic Review"],"prefix":"10.1016","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0996-1487","authenticated-orcid":false,"given":"Erin F.","family":"Barreto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0338-7784","authenticated-orcid":false,"given":"Andrew D.","family":"Rule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5502-5975","authenticated-orcid":false,"given":"M. Hassan","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kianoush B.","family":"Kashani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Lieske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia J.","family":"Erwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Steckelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ognjen","family":"Gajic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra L.","family":"Kane-Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.mayocp.2018.08.002_bib1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ccc.2006.02.003","article-title":"Drug-associated renal dysfunction","volume":"22","author":"Taber","year":"2006","journal-title":"Crit Care Clin"},{"issue":"11","key":"10.1016\/j.mayocp.2018.08.002_bib2","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1093\/ndt\/gfl399","article-title":"Use of renal risk drugs in hospitalized patients with impaired renal function\u2014an underestimated problem?","volume":"21","author":"Blix","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1016\/j.mayocp.2018.08.002_bib3","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/ki.2009.353","article-title":"Occurrence of adverse, often preventable, events in community hospitals involving nephrotoxic drugs or those excreted by the kidney","volume":"76","author":"Hug","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.mayocp.2018.08.002_bib4","series-title":"Draft\u2014Guidance for industry: pharmacokinetics in patients with impaired renal function\u2014study design,\u00a0data analysis, and impact on dosing and labeling","year":"2010"},{"issue":"3","key":"10.1016\/j.mayocp.2018.08.002_bib5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/cpt.729","article-title":"Assessment of glomerular filtration rate in health and disease: a state of the art review","volume":"102","author":"Levey","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.mayocp.2018.08.002_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.mayocp.2018.08.002_bib7","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.mayocp.2018.08.002_bib8","author":"Wells"},{"key":"10.1016\/j.mayocp.2018.08.002_bib9","series-title":"A\u00a0Dictionary of Epidemiology","year":"2014"},{"issue":"4","key":"10.1016\/j.mayocp.2018.08.002_bib10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some suggestions for measuring predictive performance","volume":"9","author":"Sheiner","year":"1981","journal-title":"J\u00a0Pharmacokinet Biopharm"},{"key":"10.1016\/j.mayocp.2018.08.002_bib11","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1038\/psp.2012.4","article-title":"Basic concepts in population modeling, simulation, and model-based drug development","volume":"1","author":"Mould","year":"2012","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.mayocp.2018.08.002_bib12","series-title":"Introduction to Meta-Analysis","author":"Borenstein","year":"2009"},{"issue":"2","key":"10.1016\/j.mayocp.2018.08.002_bib13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/jama.2014.5559","article-title":"How to read a systematic review and meta-analysis and apply the results to patient care: users\u2019 guides to the medical literature","volume":"312","author":"Murad","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.mayocp.2018.08.002_bib14","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/01.ftd.0000211805.89440.3d","article-title":"Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin","volume":"28","author":"Hermida","year":"2006","journal-title":"Ther Drug Monit"},{"issue":"10","key":"10.1016\/j.mayocp.2018.08.002_bib15","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1111\/aas.12808","article-title":"Standard dosing of piperacillin and meropenem fail to achieve adequate plasma concentrations in ICU patients","volume":"60","author":"Petersson","year":"2016","journal-title":"Acta Anaesthesiol Scand"},{"issue":"2","key":"10.1016\/j.mayocp.2018.08.002_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2515\/therapie:2007019","article-title":"Interest of cystatin C for individual dosing of anticancer drugs cleared by the kidneys","volume":"62","author":"Thomas","year":"2007","journal-title":"Therapie"},{"issue":"2","key":"10.1016\/j.mayocp.2018.08.002_bib17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0b013e31803bcfd2","article-title":"Estimation of the initial dose setting of vancomycin therapy with use of cystatin C as a new marker of renal function","volume":"29","author":"Tanaka","year":"2007","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1016\/j.mayocp.2018.08.002_bib18","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/j.ajkd.2016.11.016","article-title":"Cystatin C\u2013guided vancomycin dosing in critically ill patients: a quality improvement project","volume":"69","author":"Frazee","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.mayocp.2018.08.002_bib19","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ijantimicag.2010.07.015","article-title":"Clearance of vancomycin during continuous infusion in Intensive Care Unit patients: correlation with measured and estimated creatinine clearance and serum cystatin C","volume":"36","author":"Kees","year":"2010","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"10.1016\/j.mayocp.2018.08.002_bib20","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1211\/jpp.62.07.0011","article-title":"Usefulness of serum cystatin C to determine the dose of vancomycin in critically ill patients","volume":"62","author":"Suzuki","year":"2010","journal-title":"J\u00a0Pharm Pharmacol"},{"issue":"2","key":"10.1016\/j.mayocp.2018.08.002_bib21","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/AAC.00661-09","article-title":"Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function","volume":"54","author":"Tanaka","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.mayocp.2018.08.002_bib22","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00280-010-1537-0","article-title":"Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin","volume":"68","author":"Holweger","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.mayocp.2018.08.002_bib23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5414\/CP201776","article-title":"Estimation of safe and effective dose of vancomycin in MRSA-infected patients using serum cystatin C concentrations","volume":"51","author":"Chen","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.mayocp.2018.08.002_bib24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3346\/jkms.2013.28.1.48","article-title":"Serum cystatin C is a major predictor of vancomycin clearance in a population pharmacokinetic analysis of patients with normal serum creatinine concentrations","volume":"28","author":"Chung","year":"2013","journal-title":"J\u00a0Korean Med Sci"},{"issue":"1","key":"10.1016\/j.mayocp.2018.08.002_bib25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/QAD.0000000000000033","article-title":"Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women","volume":"28","author":"Baxi","year":"2014","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.mayocp.2018.08.002_bib26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40268-014-0045-9","article-title":"Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C","volume":"14","author":"Chin","year":"2014","journal-title":"Drugs R D"},{"issue":"5","key":"10.1016\/j.mayocp.2018.08.002_bib27","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/FTD.0000000000000065","article-title":"Comparison of equations with estimate renal function to predict serum vancomycin concentration in patients with spinal cord injury\u2014does the use of cystatin c improve accuracy?","volume":"36","author":"DeCarolis","year":"2014","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.mayocp.2018.08.002_bib28","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/cc13899","article-title":"Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study","volume":"18","author":"Frazee","year":"2014","journal-title":"Crit Care"},{"issue":"2","key":"10.1016\/j.mayocp.2018.08.002_bib29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/bcp.12501","article-title":"The performance of contemporary cystatin C-based GFR equations in predicting gentamicin clearance","volume":"79","author":"Chin","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.mayocp.2018.08.002_bib30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s13631-016-0136-4","article-title":"Glomerular filtration rate assessed by using creatinine and cystatin in patients treated with dabigatran","volume":"12","author":"Gessoni","year":"2016","journal-title":"Riv Ital Med Lab"},{"issue":"9","key":"10.1016\/j.mayocp.2018.08.002_bib31","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1093\/jac\/dkw171","article-title":"A\u00a0model-based analysis of the predictive performance of different renal function markers for cefepime clearance in the ICU","volume":"71","author":"Jonckheere","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.mayocp.2018.08.002_bib32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/jcph.600","article-title":"Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients","volume":"56","author":"Kees","year":"2016","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.mayocp.2018.08.002_bib33","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jiac.2016.01.024","article-title":"Comparison of predictive accuracy of teicoplanin concentration using creatinine clearance and glomerular filtration rate estimated by serum creatinine or cystatin C","volume":"22","author":"Kozono","year":"2016","journal-title":"J\u00a0Infect Chemother"},{"issue":"5","key":"10.1016\/j.mayocp.2018.08.002_bib34","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s11096-017-0522-7","article-title":"Adherence with perindopril therapy: a pilot study using therapeutic drug monitoring of perindoprilat and an evaluation of the clearance estimation","volume":"39","author":"\u0160\u00edma","year":"2017","journal-title":"Int J Clin Pharm"},{"issue":"3","key":"10.1016\/j.mayocp.2018.08.002_bib35","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/2000-1967-087","article-title":"Cystatin C vs creatinine as markers of renal function in patients on digoxin treatment","volume":"109","author":"Hallberg","year":"2004","journal-title":"Ups J Med Sci"},{"issue":"3","key":"10.1016\/j.mayocp.2018.08.002_bib36","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7150\/ijms.3.92","article-title":"Serum cystatin C levels to predict serum concentration of digoxin in Japanese patients","volume":"3","author":"Nakamura","year":"2006","journal-title":"Int J Med Sci"},{"issue":"3","key":"10.1016\/j.mayocp.2018.08.002_bib37","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1365-2125.2006.02652.x","article-title":"A\u00a0population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function","volume":"62","author":"Viberg","year":"2006","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.mayocp.2018.08.002_bib38","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1177\/0091270007305503","article-title":"Estimation of the glomerular filtration rate from serum creatinine and cystatin C with regard to therapeutic digoxin monitoring","volume":"47","author":"Garcia","year":"2007","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.mayocp.2018.08.002_bib39","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.clinbiochem.2007.01.008","article-title":"Serum cystatin C as a better marker of vancomycin clearance than serum creatinine in elderly patients","volume":"40","author":"Okamoto","year":"2007","journal-title":"Clin Biochem"},{"issue":"3","key":"10.1016\/j.mayocp.2018.08.002_bib40","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2710.2008.00905.x","article-title":"Evaluation of the clinical application of cystatin C, a new marker of the glomerular filtration rate, for the initial dose-setting of arbekacin","volume":"33","author":"Otsuka","year":"2008","journal-title":"J\u00a0Clin Pharm Ther"},{"issue":"10","key":"10.1016\/j.mayocp.2018.08.002_bib41","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1158\/1078-0432.CCR-09-0017","article-title":"A\u00a0universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients","volume":"15","author":"Schmitt","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.mayocp.2018.08.002_bib42","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bcp.12602","article-title":"Cystatin C as a potential biomarker for dosing of renally excreted drugs","volume":"80","author":"Brou","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.mayocp.2018.08.002_bib43","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1046\/j.1365-2125.2002.01549.x","article-title":"Serum cystatin C is not a better marker of creatinine or digoxin clearance than serum creatinine","volume":"53","author":"O\u2019Riordan","year":"2002","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.mayocp.2018.08.002_bib44","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2710.2008.00932.x","article-title":"Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin","volume":"33","author":"Halacova","year":"2008","journal-title":"J\u00a0Clin Pharm Ther"},{"issue":"8","key":"10.1016\/j.mayocp.2018.08.002_bib45","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.mayocp.2018.08.002_bib46","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40262-015-0236-8","article-title":"Reporting Guidelines for Clinical Pharmacokinetic Studies: the ClinPK statement","volume":"54","author":"Kanji","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.mayocp.2018.08.002_bib47","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1515\/CCLM.2011.167","article-title":"Focusing on the clinical impact of standardization of creatinine measurements: a report by the EFCC Working Group on Creatinine Standardization","volume":"49","author":"Delanghe","year":"2011","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"10.1016\/j.mayocp.2018.08.002_bib48","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/phar.2149","article-title":"Innovative use of novel biomarkers to improve the safety of renally eliminated and nephrotoxic medications","volume":"38","author":"Barreto","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.mayocp.2018.08.002_bib49","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1053\/j.ajkd.2013.03.027","article-title":"Update on cystatin C: incorporation into clinical practice","volume":"62","author":"Shlipak","year":"2013","journal-title":"Am J Kidney Dis"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561961830586X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561961830586X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:30:26Z","timestamp":1758418226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002561961830586X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S002561961830586X"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2018.08.002","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of the Renal Elimination of Drugs With Cystatin C vs Creatinine: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2018.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}